a:7:{s:8:”location”;a:1:{i:0;a:1:{i:0;a:3:{s:5:”param”;s:9:”post_type”;s:8:”operator”;s:2:”==”;s:5:”value”;s:4:”page”;}}}s:8:”position”;s:6:”normal”;s:5:”style”;s:7:”default”;s:15:”label_placement”;s:3:”top”;s:21:”instruction_placement”;s:5:”label”;s:14:”hide_on_screen”;s:0:””;s:11:”description”;s:0:””;}
VistaPath, the leading provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, today announced that VistaPath Sentinel was validated in a clinical setting after a collaboration with PathAI, a global leader in AI-powered pathology. VistaPath Sentinel is the world’s first automated tissue grossing platform.
The Sentinel is a first-of-its-kind tissue grossing platform that automates the process of receiving, assessing, and processing tissue samples. Designed to make tissue grossing faster, safer, and easier, the Sentinel uses a high-quality video system to assess specimens and create a gross report 93% faster than human technicians with 43% more accuracy. It not only improves on quality by continuously monitoring the cassette, container, and tissue to reduce mislabeling and specimen mix-up, but also increases traceability by retaining original images for downstream review.
“Despite informing a majority of clinical decisions, anatomical pathology still prepares samples for diagnosis manually, in stark contrast to other clinical lab services. Our work with PathAI has proven our ability to modernize this critical lab process,” said Timothy Spong, CEO of VistaPath. “This is a complimentary partnership of AI technologies. PathAI’s validation of the Sentinel in a clinical setting has charted the course for broader use of the device in the clinical market, following our FDA and ISO27001 compliance earlier this year.”
For customers like PathAI, the Sentinel adds another level of sophistication to their workflow by providing automated grossing, making the process faster, cheaper and with fewer errors. “We joined with a top anatomic pathology laboratory to establish a new type of modern lab, PathAI Diagnostics. This commitment to usher in a new era of precision pathology requires partners that can transform other parts of the laboratory process outside of the diagnosis itself; VistaPath offers a technology that can automate grossing,” said Dr. Andy Beck, CEO and Co-Founder of PathAI. “Implementing the Sentinel into our clinical workflow can tremendously impact our diagnostic laboratory process management with a high-quality, AI-focused solution.”
Cambridge, Massachusetts, July 28, 2022 – VistaPath, the leading provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, today announced a new collaboration with Gestalt Diagnostics of Spokane, WA, to further advance digitization in pathology labs.
The collaboration combines two AI solutions, VistaPath’s Sentinel, the world’s first automated tissue grossing platform, and Gestalt’s AI Requisition Engine (AIRE), a leading-edge AI algorithm for accessioning, to raise the bar in AI-driven pathology digitization.
Designed to make tissue grossing faster and more accurate, VistaPath’s Sentinel uses a high-quality video system to assess specimens and create a gross report 93% faster than human technicians with 43% more accuracy. It not only improves on quality by continuously monitoring the cassette, container, and tissue to reduce mislabeling and specimen mix-up, but also increases traceability by retaining original images for downstream review.
Gestalt’s AIRE drastically improves speed and accuracy over manual data entry tasks. It is an intuitive and continual learning AI algorithm that is highly scalable and accurately interprets requisition and other form types, including complicated ones. By automatically interpreting data and handwriting from scanned paper requisitions, including complicated form elements, AIRE sends an electronic order directly to the LIS, improving data quality for more timely and accurate billing.
“We‘re always looking to work with new innovators, and Gestalt was a perfect fit,” says Timothy Spong, CEO of VistaPath. “It’s a great collaboration that will help advance our collective goal of using AI solutions to digitize pathology labs.”
“Incorporating AI in the laboratory to enhance and improve manual processes is an intelligent and highly effective use of technology. By partnering with thought leaders like VistaPath to combine these two front-end functions, tests can now get into the laboratory workflow in a fraction of the time with higher accuracy,” says Lisa-Jean Clifford, COO and Chief Strategy Officer of Gestalt Diagnostics. “In these difficult employment times – this technology reduces your reliance on human resources in hiring, staff turnover, coverage for outages, in addition to providing a competitive edge.”
About VistaPath
VistaPath is modernizing pathology labs using machine augmentation. Driven by computer vision, they provide clients with significant quality, workflow, and strategic benefits with the overall goal of delivering improved results for pathologists, clinicians, and patients. The Sentinel is the company’s first product. Learn more at vistapathbio.com.
About Gestalt Diagnostics
Gestalt Diagnostics is bringing anatomic pathology into the digital age by providing enterprise solutions and services to transform anatomic pathology laboratories by providing all-inclusive technology solutions and services that enable clinicians to diagnose diseases faster and more efficiently.
